In patients with dyskinesia, the proportion of levodopa-benserazide, levodopa-carbidopa, dopaminergic agonists, and COMT inhibitors was higher than that in patients with motor complications (P < 0.05). This evidence concerns the gene COMT and Dyskinesia.